The 3D-PREDICT clinical study analyses a patient's live cancer cells, grown in Kiyatec's laboratory within a biologically-relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs.
Evidence from the company's earlier pilot study established a correlation between patient-specific predicted tumor response and actual patient clinical response to cancer therapy.
The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.
The 3D-PREDICT study is anticipated to continue through 2022.
Inova has already accrued patients into the trial and G. Larry Maxwell, MD, chairman of Obstetrics and Gynecology and co-director of Inova's Women's Health Integrated Research Center (WHIRC) is the lead investigator.
Inova Strategic Investments, the strategic investing division of the Inova Health System, is an investor in Kiyatec.
The division invests in companies that align with Inova's strategic priorities of delivering personalized health and healthcare services.
Kiyatec develops 3D cell-based assays for use in preclinical drug discovery and clinical therapy applications. It has a contract research project portfolio performing standard and custom cell-based assays for biopharma clients, as well as research and development contracts funded by the National Cancer Institute to develop 3D cell culture models for breast cancer, glioblastoma, and lung cancer.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review